About this Journal Submit a Manuscript Table of Contents
Journal of Biomedicine and Biotechnology
Volume 2012 (2012), Article ID 950658, 17 pages
http://dx.doi.org/10.1155/2012/950658
Review Article

Salinomycin as a Drug for Targeting Human Cancer Stem Cells

1Institute of Immunology, University of Heidelberg, Im Neuenheimer Feld 305, 69120 Heidelberg, Germany
2Center and Network for Targeted Oncology, Clinical Research Division, Muehlackerweg 8, 69239 Heidelberg, Germany

Received 23 August 2012; Accepted 4 October 2012

Academic Editor: Adam Huczynski

Copyright © 2012 Cord Naujokat and Roman Steinhart. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. T. Reya, S. J. Morrison, M. F. Clarke, and I. L. Weissman, “Stem cells, cancer, and cancer stem cells,” Nature, vol. 414, no. 6859, pp. 105–111, 2001. View at Publisher · View at Google Scholar · View at Scopus
  2. R. Pardal, M. F. Clarke, and S. J. Morrison, “Applying the principles of stem-cell biology to cancer,” Nature Reviews Cancer, vol. 3, no. 12, pp. 895–902, 2003. View at Scopus
  3. R. J. Ward and P. B. Dirks, “Cancer stem cells: at the headwaters of tumor development,” Annual Review of Pathology, vol. 2, pp. 175–189, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. J. E. Dick, “Stem cell concepts renew cancer research,” Blood, vol. 112, no. 13, pp. 4793–4807, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. N. Y. Frank, T. Schatton, and M. H. Frank, “The therapeutic promise of the cancer stem cell concept,” Journal of Clinical Investigation, vol. 120, no. 1, pp. 41–50, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. P. C. Hermann, S. Bhaskar, M. Cioffi, and C. Heeschen, “Cancer stem cells in solid tumors,” Seminars in Cancer Biology, vol. 20, no. 2, pp. 77–84, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. H. Clevers, “The cancer stem cell: premises, promises and challenges,” Nature Medicine, vol. 17, no. 3, pp. 313–319, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. J. A. Magee, E. Piskounova, and S. J. Morrison, “Cancer stem cells: impact, heterogeneity, and uncertainty,” Cancer Cell, vol. 21, no. 3, pp. 283–296, 2012. View at Publisher · View at Google Scholar
  9. M. F. Clarke, J. E. Dick, P. B. Dirks et al., “Cancer stem cells—perspectives on current status and future directions: AACR workshop on cancer stem cells,” Cancer Research, vol. 66, no. 19, pp. 9339–9344, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. C. J. Creighton, X. Li, M. Landis et al., “Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 33, pp. 13820–13825, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. R. Tehranchi, P. S. Woll, K. Anderson et al., “Persistent malignant stem cells in del(5q) myelodysplasia in remission,” New England Journal of Medicine, vol. 363, no. 11, pp. 1025–1037, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. J. M. Gerber, B. D. Smith, B. Ngwang, et al., “A clinically relevant population of leukemic CD34+CD38-cells in acute myeloid leukemia,” Blood, vol. 119, no. 15, pp. 3571–3577, 2012.
  13. Y. An and W. M. Ongkeko, “ABCG2: the key to chemoresistance in cancer stem cells?” Expert Opinion on Drug Metabolism and Toxicology, vol. 5, no. 12, pp. 1529–1542, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. M. Dean, “ABC transporters, drug resistance, and cancer stem cells,” Journal of Mammary Gland Biology and Neoplasia, vol. 14, no. 1, pp. 3–9, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. A. M. Calcagno, C. D. Salcido, J. P. Gillet et al., “Prolonged drug selection of breast cancer cells and enrichment of cancer stem cell characteristics,” Journal of the National Cancer Institute, vol. 102, no. 21, pp. 1637–1652, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. D. Fuchs, V. Daniel, M. Sadeghi, G. Opelz, and C. Naujokat, “Salinomycin overcomes ABC transporter-mediated multidrug and apoptosis resistance in human leukemia stem cell-like KG-1a cells,” Biochemical and Biophysical Research Communications, vol. 394, no. 4, pp. 1098–1104, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. K. Moitra, H. Lou, and M. Dean, “Multidrug efflux pumps and cancer stem cells: insights into multidrug resistance and therapeutic development,” Clinical Pharmacology and Therapeutics, vol. 89, no. 4, pp. 491–502, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. Y. Teng, X. Wang, Y. Wang, and D. Ma, “Wnt/β-catenin signaling regulates cancer stem cells in lung cancer A549 cells,” Biochemical and Biophysical Research Communications, vol. 392, no. 3, pp. 373–379, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. J. Yeung, M. T. Esposito, A. Gandillet et al., “β-catenin mediates the establishment and drug resistance of MLL leukemic stem cells,” Cancer Cell, vol. 18, no. 6, pp. 606–618, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. N. Takebe, P. J. Harris, R. Q. Warren, and S. P. Ivy, “Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways,” Nature Reviews Clinical Oncology, vol. 8, no. 2, pp. 97–106, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. M. Janikowa and J. Skarda, “Differentiation pathways in carcinogenesis and in chemo- and radioresistance,” Neoplasma, vol. 59, no. 1, pp. 6–17, 2012. View at Publisher · View at Google Scholar
  22. C. Zhao, A. Chen, C. H. Jamieson et al., “Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia,” Nature, vol. 458, no. 7239, pp. 776–779, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. M. Kobune, R. Takimoto, K. Murase et al., “Drug resistance is dramatically restored by hedgehog inhibitors in CD34+ leukemic cells,” Cancer Science, vol. 100, no. 5, pp. 948–955, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. Z. Wang, Y. Li, D. Kong et al., “Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway,” Cancer Research, vol. 69, no. 6, pp. 2400–2407, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. S. Ma, T. K. Lee, B. J. Zheng, K. W. Chan, and X. Y. Guan, “CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway,” Oncogene, vol. 27, no. 12, pp. 1749–1758, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. H. Korkaya, A. Paulson, E. Charafe-Jauffret et al., “Regulation of mammary stem/progenitor cells by PTEN/Akt/β-catenin signaling,” PLoS Biology, vol. 7, no. 6, Article ID e1000121, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. E. Gallmeier, P. C. Hermann, M. T. Mueller et al., “Inhibition of ataxia telangiectasia- and Rad3-related function abrogates the in vitro and in vivo tumorigenicity of human colon cancer cells through depletion of the CD133+ tumor-initiating cell fraction,” Stem Cells, vol. 29, no. 3, pp. 418–429, 2011. View at Publisher · View at Google Scholar · View at Scopus
  28. D. Hambardzumyan, O. J. Becher, M. K. Rosenblum, P. P. Pandolfi, K. Manova-Todorova, and E. C. Holland, “PI3K pathway regulates survival of cancer stem cells residing in the perivascular niche following radiation in medulloblastoma in vivo,” Genes and Development, vol. 22, no. 4, pp. 436–448, 2008. View at Publisher · View at Google Scholar · View at Scopus
  29. R. Hill and H. Wu, “PTEN, stem cells, and cancer stem cells,” Journal of Biological Chemistry, vol. 284, no. 18, pp. 11755–11759, 2009. View at Publisher · View at Google Scholar · View at Scopus
  30. A. M. Martelli, C. Evangelisti, M. Y. Follo et al., “Targeting the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin signaling network in cancer stem cells,” Current Medicinal Chemistry, vol. 18, no. 18, pp. 2715–2726, 2011. View at Publisher · View at Google Scholar · View at Scopus
  31. C. Ginestier, M. H. Hur, E. Charafe-Jauffret et al., “ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome,” Cell Stem Cell, vol. 1, no. 5, pp. 555–567, 2007. View at Publisher · View at Google Scholar · View at Scopus
  32. S. J. Dylla, L. Beviglia, I. K. Park et al., “Colorectal cancer stem cells are enriched in xenogeneic tumors following chemotherapy,” PLoS ONE, vol. 3, no. 6, Article ID e2428, 2008. View at Publisher · View at Google Scholar · View at Scopus
  33. O. Awad, J. T. Yustein, P. Shah et al., “High ALDH activity identifies chemotherapy-resistant Ewing's sarcoma stem cells that retain sensitivity to EWS-Fli1 inhibition,” PLoS ONE, vol. 5, no. 11, Article ID e13943, 2010. View at Publisher · View at Google Scholar · View at Scopus
  34. E. Charafe-Jauffret, C. Ginestier, F. Iovino et al., “Aldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer,” Clinical Cancer Research, vol. 16, no. 1, pp. 45–55, 2010. View at Publisher · View at Google Scholar · View at Scopus
  35. S. Bao, Q. Wu, R. E. McLendon et al., “Glioma stem cells promote radioresistance by preferential activation of the DNA damage response,” Nature, vol. 444, no. 7120, pp. 756–760, 2006. View at Publisher · View at Google Scholar · View at Scopus
  36. T. M. Phillips, W. H. McBride, and F. Pajonk, “The response of CD24-/low/CD44+ breast cancer-initiating cells to radiation,” Journal of the National Cancer Institute, vol. 98, no. 24, pp. 1777–1785, 2006. View at Publisher · View at Google Scholar · View at Scopus
  37. M. Diehn, R. W. Cho, N. A. Lobo et al., “Association of reactive oxygen species levels and radioresistance in cancer stem cells,” Nature, vol. 458, no. 7239, pp. 780–783, 2009. View at Publisher · View at Google Scholar · View at Scopus
  38. M. Ropolo, A. Daga, F. Griffero et al., “Comparative analysis of DNA repair in stem and nonstem glioma cell cultures,” Molecular Cancer Research, vol. 7, no. 3, pp. 383–392, 2009. View at Publisher · View at Google Scholar · View at Scopus
  39. A. Viale, F. De Franco, A. Orleth et al., “Cell-cycle restriction limits DNA damage and maintains self-renewal of leukaemia stem cells,” Nature, vol. 457, no. 7225, pp. 51–56, 2009. View at Publisher · View at Google Scholar · View at Scopus
  40. F. Pajonk, E. Vlashi, and W. H. McBride, “Radiation resistance of cancer stem cells: the 4 R's of radiobiology revisited,” Stem Cells, vol. 28, no. 4, pp. 639–648, 2010. View at Publisher · View at Google Scholar · View at Scopus
  41. M. L. Guzman, C. F. Swiderski, D. S. Howard et al., “Preferential induction of apoptosis for primary human leukemic stem cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 25, pp. 16220–16225, 2002. View at Publisher · View at Google Scholar · View at Scopus
  42. J. Zhou, H. Zhang, P. Gu, J. Bai, J. B. Margolick, and Y. Zhang, “NF-κB pathway inhibitors preferentially inhibit breast cancer stem-like cells,” Breast Cancer Research and Treatment, vol. 111, no. 3, pp. 419–427, 2008. View at Publisher · View at Google Scholar · View at Scopus
  43. M. Liu, T. Sakamaki, M. C. Casimiro et al., “The canonical NF-κB pathway governs mammary tumorigenesis in transgenic mice and tumor stem cell expansion,” Cancer Research, vol. 70, no. 24, pp. 10464–10473, 2010. View at Publisher · View at Google Scholar · View at Scopus
  44. M. Baumann, M. Krause, and R. Hill, “Exploring the role of cancer stem cells in radioresistance,” Nature Reviews Cancer, vol. 8, no. 7, pp. 545–554, 2008. View at Publisher · View at Google Scholar · View at Scopus
  45. S. H. Chiou, C. L. Kao, Y. W. Chen et al., “Identification of CD133-positive radioresistant cells in atypical teratoid/rhabdoid tumor,” PLoS ONE, vol. 3, no. 5, Article ID e2090, 2008. View at Publisher · View at Google Scholar · View at Scopus
  46. L. S. Piao, W. Hur, T. K. Kim, et al., “CD133(+) liver cancer stem cells modulate radioresistance in human hepatocellular carcinoma,” Cancer Letters, vol. 315, no. 2, pp. 129–137, 2012. View at Publisher · View at Google Scholar
  47. M. Todaro, M. P. Alea, A. B. Di Stefano et al., “Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4,” Cell Stem Cell, vol. 1, no. 4, pp. 389–402, 2007. View at Publisher · View at Google Scholar · View at Scopus
  48. M. G. Francipane, M. P. Alea, Y. Lombardo, M. Todaro, J. P. Medema, and G. Stassi, “Crucial role of interleukin-4 in the survival of colon cancer stem cells,” Cancer Research, vol. 68, no. 11, pp. 4022–4025, 2008. View at Publisher · View at Google Scholar · View at Scopus
  49. G. Liu, X. Yuan, Z. Zeng et al., “Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma,” Molecular Cancer, vol. 5, p. 67, 2006. View at Publisher · View at Google Scholar · View at Scopus
  50. F. A. E. Kruyt and J. J. Schuringa, “Apoptosis and cancer stem cells: implications for apoptosis targeted therapy,” Biochemical Pharmacology, vol. 80, no. 4, pp. 423–430, 2010. View at Publisher · View at Google Scholar · View at Scopus
  51. Y. Zhou, Y. Zhou, T. Shingu, et al., “Metabolic alterations in highly tumorigenic glioblastoma cells: preference for hypoxia and high dependency on glycolysis,” Journal of Biological Chemistry, vol. 286, no. 37, pp. 32843–32853, 2011.
  52. C. Calabrese, H. Poppleton, M. Kocak et al., “A perivascular Niche for brain tumor stem cells,” Cancer Cell, vol. 11, no. 1, pp. 69–82, 2007. View at Publisher · View at Google Scholar · View at Scopus
  53. H. Korkaya, S. Liu, and M. S. Wicha, “Breast cancer stem cells, cytokine networks, and the tumor microenvironment,” Journal of Clinical Investigation, vol. 121, no. 10, pp. 3804–3809, 2011. View at Publisher · View at Google Scholar
  54. C. Lagadec, E. Vlashi, L. Della Donna et al., “Survival and self-renewing capacity of breast cancer initiating cells during fractionated radiation treatment,” Breast Cancer Research, vol. 12, no. 1, p. R13, 2010. View at Publisher · View at Google Scholar · View at Scopus
  55. F. Reim, Y. Dombrowski, C. Ritter et al., “Immunoselection of breast and ovarian cancer cells with trastuzumab and natural killer cells: selective escape of CD44high/CD24low/HER2low breast cancer stem cells,” Cancer Research, vol. 69, no. 20, pp. 8058–8066, 2009. View at Publisher · View at Google Scholar · View at Scopus
  56. T. Schatton, U. Schütte, N. Y. Frank et al., “Modulation of T-cell activation by malignant melanoma initiating cells,” Cancer Research, vol. 70, no. 2, pp. 697–708, 2010. View at Publisher · View at Google Scholar · View at Scopus
  57. A. Wu, J. Wei, L. Y. Kong et al., “Glioma cancer stem cells induce immunosuppressive macrophages/microglia,” Neuro-Oncology, vol. 12, no. 11, pp. 1113–1125, 2010. View at Publisher · View at Google Scholar · View at Scopus
  58. M. R. Kim, H. K. Choi, K. B. Cho, H. S. Kim, and K. W. Kang, “Involvement of Pin1 induction in epithelial-mesenchymal transition of tamoxifen-resistant breast cancer cells,” Cancer Science, vol. 100, no. 10, pp. 1834–1841, 2009. View at Publisher · View at Google Scholar · View at Scopus
  59. X. Chen, S. Lingala, S. Khoobyari, J. Nolta, M. A. Zern, and J. Wu, “Epithelial mesenchymal transition and hedgehog signaling activation are associated with chemoresistance and invasion of hepatoma subpopulations,” Journal of Hepatology, 2011. View at Publisher · View at Google Scholar · View at Scopus
  60. M. Q. Gao, Y. P. Choi, S. Kang, J. H. Youn, and N. H. Cho, “CD24+ cells from hierarchically organized ovarian cancer are enriched in cancer stem cells,” Oncogene, vol. 29, no. 18, pp. 2672–2680, 2010. View at Publisher · View at Google Scholar · View at Scopus
  61. M. A. G. Essers and A. Trumpp, “Targeting leukemic stem cells by breaking their dormancy,” Molecular Oncology, vol. 4, no. 5, pp. 443–450, 2010. View at Publisher · View at Google Scholar · View at Scopus
  62. L. Li and R. Bhatia, “Stem cell quiescence,” Clinical Cancer Research, vol. 17, no. 15, pp. 4936–4941, 2011. View at Publisher · View at Google Scholar · View at Scopus
  63. R. Sottocornola and C. Lo Celso, “Dormancy in the stem cell niche,” Stem Cell Research & Therapy, vol. 3, no. 2, p. 10, 2012.
  64. M. Maugeri-Saccà, P. Vigneri, and R. De Maria, “Cancer stem cells and chemosensitivity,” Clinical Cancer Research, vol. 17, no. 15, pp. 4942–4947, 2011. View at Publisher · View at Google Scholar · View at Scopus
  65. B. Lu, R. Morrison, S. M. Schleicher et al., “Targeting the mechanisms of resistance to chemotherapy and radiotherapy with the cancer stem cell hypothesis,” Journal of Oncology, vol. 2011, Article ID 941876, 13 pages, 2011. View at Publisher · View at Google Scholar · View at Scopus
  66. B. Malik and D. Nie, “Cancer stem cells and resistance to chemo and radio therapy,” Frontiers in Bioscience, vol. 4, pp. 2142–2149, 2012.
  67. F. Yu, H. Yao, P. Zhu et al., “let-7 regulates self renewal and tumorigenicity of breast cancer cells,” Cell, vol. 131, no. 6, pp. 1109–1123, 2007. View at Publisher · View at Google Scholar · View at Scopus
  68. X. Li, M. T. Lewis, J. Huang et al., “Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy,” Journal of the National Cancer Institute, vol. 100, no. 9, pp. 672–679, 2008. View at Publisher · View at Google Scholar · View at Scopus
  69. P. P. L. Chiu, H. Jiang, and J. E. Dick, “Leukemia-initiating cells in human T-lymphoblastic leukemia exhibit glucocorticoid resistance,” Blood, vol. 116, no. 24, pp. 5268–5279, 2010. View at Publisher · View at Google Scholar · View at Scopus
  70. F. Al-Ejeh, C. E. Smart, B. J. Morrison et al., “Breast cancer stem cells: treatment resistance and therapeutic opportunities,” Carcinogenesis, vol. 32, no. 5, pp. 650–658, 2011. View at Publisher · View at Google Scholar · View at Scopus
  71. M. A. Velasco-Velázquez, V. M. Popov, M. P. Lisanti, and R. G. Pestell, “The role of breast cancer stem cells in metastasis and therapeutic implications,” American Journal of Pathology, vol. 179, no. 1, pp. 2–11, 2011. View at Publisher · View at Google Scholar · View at Scopus
  72. G. Ghiaur, J. Gerber, and R. J. Jones, “Cancer stem cells and minimal residual disease,” Stem Cells, vol. 30, no. 1, pp. 89–93, 2012. View at Publisher · View at Google Scholar
  73. S. Sell, “On the stem cell origin of cancer,” American Journal of Pathology, vol. 176, no. 6, pp. 2584–2594, 2010. View at Publisher · View at Google Scholar · View at Scopus
  74. B. B. S. Zhou, H. Zhang, M. Damelin, K. G. Geles, J. C. Grindley, and P. B. Dirks, “Tumour-initiating cells: challenges and opportunities for anticancer drug discovery,” Nature Reviews Drug Discovery, vol. 8, no. 10, pp. 806–823, 2009. View at Publisher · View at Google Scholar · View at Scopus
  75. S. P. McDermott and M. S. Wicha, “Targeting breast cancer stem cells,” Molecular Oncology, vol. 4, no. 5, pp. 404–419, 2010. View at Publisher · View at Google Scholar · View at Scopus
  76. G. J. Prud'homme, “Cancer stem cells and novel targets for antitumor strategies,” Current Pharmaceutical Design, vol. 18, no. 19, pp. 2838–2849, 2012.
  77. N. P. Nguyen, F. S. Almeida, A. Chi et al., “Molecular biology of breast cancer stem cells: potential clinical applications,” Cancer Treatment Reviews, vol. 36, no. 6, pp. 485–491, 2010. View at Publisher · View at Google Scholar · View at Scopus
  78. A. Lorico and G. Rappa, “Phenotypic heterogeneity of breast cancer stem cells,” Journal of Oncology, vol. 2011, Article ID 135039, 6 pages, 2011. View at Publisher · View at Google Scholar · View at Scopus
  79. J. E. Visvader and G. J. Lindeman, “Cancer stem cells: current status and evolving complexities,” Cell Stem Cell, vol. 10, no. 6, pp. 717–728, 2012.
  80. M. Shackleton, E. Quintana, E. R. Fearon, and S. J. Morrison, “Heterogeneity in cancer: cancer stem cells versus clonal evolution,” Cell, vol. 138, no. 5, pp. 822–829, 2009. View at Publisher · View at Google Scholar · View at Scopus
  81. M. T. Mueller, P. C. Hermann, J. Witthauer et al., “Combined targeted treatment to eliminate tumorigenic cancer stem cells in human pancreatic cancer,” Gastroenterology, vol. 137, no. 3, pp. 1102–1113, 2009. View at Publisher · View at Google Scholar · View at Scopus
  82. C. Y. Park, D. Tseng, and I. L. Weissman, “Cancer stem cell-directed therapies: recent data from the laboratory and clinic,” Molecular Therapy, vol. 17, no. 2, pp. 219–230, 2009. View at Publisher · View at Google Scholar · View at Scopus
  83. S. Liu and M. S. Wicha, “Targeting breast cancer stem cells,” Journal of Clinical Oncology, vol. 28, no. 25, pp. 4006–4012, 2010. View at Publisher · View at Google Scholar · View at Scopus
  84. M. R. Bardsley, V. J. Horvth, D. T. Asuzu et al., “Kitlow stem cells cause resistance to kit/platelet-derived growth factor α inhibitors in murine gastrointestinal stromal tumors,” Gastroenterology, vol. 139, no. 3, pp. 942–952, 2010. View at Publisher · View at Google Scholar · View at Scopus
  85. C. Gong, H. Yao, Q. Liu et al., “Markers of tumor-initiating cells predict chemoresistance in breast cancer,” PLoS ONE, vol. 5, no. 12, Article ID e15630, 2010. View at Publisher · View at Google Scholar · View at Scopus
  86. P. S. Oak, F. Kopp, C. Thakur, et al., “Combinatorial treatment of mammospheres with trastuzumab and salinomycin efficiently targets HER2-positve cancer cells and cancer stem cells,” International Journal of Cancer. In press. View at Publisher · View at Google Scholar
  87. G. N. Zhang, Y. Liang, L. J. Zhou, et al., “Combination of salinomycin and gemcitabine eliminates pancreatic cancer cells,” Cancer Letters, vol. 313, no. 2, pp. 137–144, 2011. View at Publisher · View at Google Scholar
  88. Y. Zhang, H. Zhang, X. Wang, J. Wang, X. Zhang, and Q. Zhang, “The eradication of breast cancer and cancer stem cells using octreotide modified paclitaxel active targeting micelles and salinomycin passive targeting micelles,” Biomaterials, vol. 33, no. 2, pp. 679–691, 2012. View at Publisher · View at Google Scholar
  89. J. H. Kim, M. Chae, W. K. Kim et al., “Salinomycin sensitizes cancer cells to the effects of doxorubicin and etoposide treatment by increasing DNA damage and reducing p21 protein,” British Journal of Pharmacology, vol. 162, no. 3, pp. 773–784, 2011. View at Publisher · View at Google Scholar · View at Scopus
  90. J. H. Kim, H. I. Yoo, H. S. Kang, J. Ro, and S. Yoon, “Salinomycin sensitizes antimitotic drugs-treated cancer cells by increasing apoptosis via the prevention of G2 arrest,” Biochemical and Biophysical Research Commununications, vol. 418, no. 1, pp. 98–103, 2012. View at Publisher · View at Google Scholar
  91. J. Nautiyal, S. S. Kanwar, Y. Yu, and A. P. N. Majumdar, “Combination of dasatinib and curcumin eliminates chemo-resistant colon cancer cells,” Journal of Molecular Signaling, p. 7, 2011. View at Publisher · View at Google Scholar · View at Scopus
  92. V. Rausch, L. Liu, G. Kallifatidis et al., “Synergistic activity of sorafenib and sulforaphane abolishes pancreatic cancer stem cell characteristics,” Cancer Research, vol. 70, no. 12, pp. 5004–5013, 2010. View at Publisher · View at Google Scholar · View at Scopus
  93. G. Kallifatidis, S. Labsch, V. Rausch et al., “Sulforaphane increases drug-mediated cytotoxicity toward cancer stem-like cells of pancreas and prostate,” Molecular Therapy, vol. 19, no. 1, pp. 188–195, 2011. View at Publisher · View at Google Scholar · View at Scopus
  94. A. Vazquez-Martin, C. Oliveras-Ferraros, S. Del Barco, B. Martin-Castillo, and J. A. Menendez, “The anti-diabetic drug metformin suppresses self-renewal and proliferation of trastuzumab-resistant tumor-initiating breast cancer stem cells,” Breast Cancer Research and Treatment, vol. 126, no. 2, pp. 355–364, 2011. View at Publisher · View at Google Scholar · View at Scopus
  95. S. Cufi, B. Corominas-Faja, A. Vazquez-Martin, et al., “Metformin-induced preferential killing of breast cancer initiating CD44+CD24-/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts,” Oncotarget, vol. 3, no. 4, pp. 395–398, 2012.
  96. R. Epelbaum, M. Schaffer, B. Vizel, V. Badmaev, and G. Bar-Sela, “Curcumin and gemcitabine in patients with advanced pancreatic cancer,” Nutrition and Cancer, vol. 62, no. 8, pp. 1137–1141, 2010. View at Publisher · View at Google Scholar · View at Scopus
  97. M. Bayet-Robert, F. Kwiatkowski, M. Leheurteur et al., “Phase I dose escalation trial of docetaxel plus curcumin in patients with advanced and metastatic breast cancer,” Cancer Biology and Therapy, vol. 9, no. 1, 2010. View at Scopus
  98. B. Martin-Castillo, J. Dorca, A. Vazquez-Martin et al., “Incorporating the antidiabetic drug metformin in HER2-positive breast cancer treated with neo-adjuvant chemotherapy and trastuzumab: an ongoing clinical-translational research experience at the Catalan Institute of Oncology,” Annals of Oncology, vol. 21, no. 1, pp. 187–189, 2010. View at Scopus
  99. M. Kanai, K. Yoshimura, M. Asada et al., “A phase I/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancer,” Cancer Chemotherapy and Pharmacology, vol. 68, no. 1, pp. 157–164, 2011. View at Publisher · View at Google Scholar · View at Scopus
  100. G. Z. Rocha, M. M. Dias, E. R. Ropelle et al., “Metformin amplifies chemotherapy-induced AMPK activation and antitumoral growth,” Clinical Cancer Research, vol. 17, no. 12, pp. 3993–4005, 2011. View at Publisher · View at Google Scholar · View at Scopus
  101. M. J. MacKenzie, S. Ernst, C. Johnson, and E. Winquist, “A phase I study of temsirolimus and metformin in advanced solid tumours,” Investigational New Drugs, pp. 1–6, 2010. View at Publisher · View at Google Scholar · View at Scopus
  102. Y. Miyazaki, M. Shibuya, and H. Sugawara, “Salinomycin, a new polyether antibiotic,” Journal of Antibiotics, vol. 27, no. 11, pp. 814–821, 1974. View at Scopus
  103. H. Kinashi, N. Otake, and H. Yonehara, “The structure of salinomycin, a new member of the polyether antibiotics,” Tetrahedron Letters, vol. 49, pp. 4955–4958, 1973. View at Scopus
  104. R. Steinhart, K. H. Berghauser, B. Steinhart, C. Martschoke, L. Hojer, and C. Naujokat, “Breast cancer metastasis regression by salinomycin,” Case Reports in Oncology. In press.
  105. B. Steinhart, A. Steinhart, R. Steinhart, K. Muth, M. Muth, and C. Naujokat, “Clinical activity of salinomycin in human advanced vulvar cancer,” Case Reports in Oncology. In press.
  106. R. J. Winquist, D. M. Boucher, M. Wood, and B. F. Furey, “Targeting cancer stem cells for more effective therapies: taking out cancer's locomotive engine,” Biochemical Pharmacology, vol. 78, no. 4, pp. 326–334, 2009. View at Publisher · View at Google Scholar · View at Scopus
  107. B. T. Kawasaki, E. M. Hurt, T. Mistree, and W. L. Farrar, “Targeting cancer stem cells with phytochemicals,” Molecular Interventions, vol. 8, no. 4, pp. 174–184, 2008. View at Publisher · View at Google Scholar · View at Scopus
  108. C. Naujokat, D. Fuchs, and G. Opelz, “Salinomycin in cancer: a new mission for an old agent,” Molecular Medicine Reports, vol. 3, no. 4, pp. 555–559, 2010. View at Publisher · View at Google Scholar · View at Scopus
  109. C. Naujokat and S. Laufer, “Salinomycin, a candidate drug for the elimination of cancer stem cells,” in Role of Cancer Stem Cells in Cancer Biology and Therapy, T. Dittmar, E. Mihich, and K. S. Z. Zänker, Eds., Science Publishers, New Hampshire, NH, USA, 2013.
  110. Y. Li, M. S. Wicha, S. J. Schwartz, and D. Sun, “Implications of cancer stem cell theory for cancer chemoprevention by natural dietary compounds,” Journal of Nutritional Biochemistry, vol. 22, no. 9, pp. 799–806, 2011. View at Publisher · View at Google Scholar · View at Scopus
  111. J. Burnett, B. Newman, and D. Sun, “Targeting cancer stem cells with natural products,” Current Drug Targets, vol. 13, no. 8, pp. 1054–1064, 2012. View at Publisher · View at Google Scholar
  112. C. Ginestier, S. Liu, M. E. Diebel et al., “CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts,” Journal of Clinical Investigation, vol. 120, no. 2, pp. 485–497, 2010. View at Publisher · View at Google Scholar · View at Scopus
  113. J. A. Low and F. J. De Sauvage, “Clinical experience with hedgehog pathway inhibitors,” Journal of Clinical Oncology, vol. 28, no. 36, pp. 5321–5326, 2010. View at Publisher · View at Google Scholar · View at Scopus
  114. A. Gould and S. Missailidis, “Targeting the Hedgehog pathway: the development of cyclopamine and the development of anti-cancer drugs targeting the Hedgehog pathway,” Mini-Reviews in Medicinal Chemistry, vol. 11, no. 3, pp. 200–213, 2011. View at Publisher · View at Google Scholar · View at Scopus
  115. O. K. Okamoto and J. F. Perez, “Targeting cancer stem cells with monoclonal antibodies: a new perspective in cancer therapy and diagnosis,” Expert Review of Molecular Diagnostics, vol. 8, no. 4, pp. 387–393, 2008. View at Publisher · View at Google Scholar · View at Scopus
  116. M. P. Deonarain, C. A. Kousparou, and A. A. Epenetos, “Antibodies targeting cancer stem cells: a new paradigm in immunotherapy?” mAbs, vol. 1, no. 1, pp. 12–25, 2009. View at Publisher · View at Google Scholar · View at Scopus
  117. R. Majeti, “Monoclonal antibody therapy directed against human acute myeloid leukemia stem cells,” Oncogene, vol. 30, no. 9, pp. 1009–1019, 2011. View at Publisher · View at Google Scholar · View at Scopus
  118. H. A. Hirsch, D. Iliopoulos, P. N. Tsichlis, and K. Struhl, “Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission,” Cancer Research, vol. 69, no. 19, pp. 7507–7511, 2009. View at Publisher · View at Google Scholar · View at Scopus
  119. S. D. Del Barco, A. Vazquez-Martin, S. Cufi, et al., “Metformin: multi-faceted protection against cancer,” Oncotarget, vol. 2, no. 12, pp. 896–917, 2012.
  120. R. Rattan, R. Ali Fehmi, and A. Munkarah, “Metformin: an emerging new therapeutic option for targeting cancer stem cells and metastasis,” Journal of Oncology, vol. 2012, Article ID 928127, 12 pages, 2012. View at Publisher · View at Google Scholar
  121. G. J. Prud'Homme, Y. Glinka, A. Toulina, O. Ace, V. Subramaniam, and S. Jothy, “Breast cancer stem-like cells are inhibited by a non-toxic aryl hydrocarbon receptor agonist,” PLoS ONE, vol. 5, no. 11, Article ID e13831, 2010. View at Publisher · View at Google Scholar · View at Scopus
  122. E. Sachlos, R. M. Risueno, S. Laroonde, et al., “Identification of drugs including a dopamine receptor antagonist that selectively target cancer stem cells,” Cell, vol. 149, no. 6, pp. 1284–1297, 2012.
  123. V. B. Mathema, Y. S. Koh, B. C. Thakuri, and M. Sillanpää, “Parthenolide, a sesquiterpene lactone, expresses multiple anti-cancer and anti-inflammatory activities,” Inflammation, pp. 1–6, 2011. View at Publisher · View at Google Scholar · View at Scopus
  124. T. V. Kourelis and R. D. Siegel, “Metformin and cancer: new applications for an old drug,” Medical Oncology, pp. 1–14, 2011. View at Publisher · View at Google Scholar · View at Scopus
  125. D. Fuchs, A. Heinold, G. Opelz, V. Daniel, and C. Naujokat, “Salinomycin induces apoptosis and overcomes apoptosis resistance in human cancer cells,” Biochemical and Biophysical Research Communications, vol. 390, no. 3, pp. 743–749, 2009. View at Publisher · View at Google Scholar · View at Scopus
  126. D. Lu, M. Y. Choi, J. Yu, J. E. Castro, T. J. Kipps, and D. A. Carson, “Salinomycin inhibits Wnt signaling and selectively induces apoptosis in chronic lymphocytic leukemia cells,” Proceedings of the National Academy of Science USA, vol. 108, no. 32, pp. 13253–13257, 2011. View at Publisher · View at Google Scholar
  127. K. Y. Kim, S. N. Yu, S. Y. Lee, et al., “Salinomycin-induced apoptosis of human prostate cancer cells due to accumulated reactive oxygen species and mitochondrial membrane depolarization,” Biochemical and Biophysical Research Communications, vol. 413, no. 1, pp. 80–86, 2011. View at Publisher · View at Google Scholar
  128. P. B. Gupta, T. T. Onder, G. Jiang et al., “Identification of selective inhibitors of cancer stem cells by high-throughput screening,” Cell, vol. 138, no. 4, pp. 645–659, 2009. View at Publisher · View at Google Scholar · View at Scopus
  129. T. T. Dong, H. M. Zhou, L. L. Wang, B. Feng, B. Lv, and M. H. Zheng, “Salinomycin selectively targets 'CD133+' cell subpopulations and decreases malignant traits in colorectal cancer lines,” Annals of Surgical Oncology, vol. 18, no. 6, pp. 1797–1804, 2011. View at Publisher · View at Google Scholar · View at Scopus
  130. Y. Wang, “Effects of salinomycin on cancer stem cell in human lung adenocarcinoma A549 cells,” Medicinal Chemistry, vol. 7, no. 2, pp. 106–111, 2011. View at Scopus
  131. Q. M. Zhi, X. H. Chen, J. Ji, et al., “Salinomycin can effectively kill ALDH(high) stem-like cells on gastric cancer,” Biomedicine and Pharmacotherapy, vol. 65, no. 7, pp. 509–515, 2011. View at Publisher · View at Google Scholar
  132. Q. L. Tang, Z. Q. Zhao, J. C. Li, et al., “Salinomycin inhibits osteosarcoma by targeting its tumor stem cells,” Cancer Letters, vol. 311, no. 1, pp. 113–121, 2011. View at Publisher · View at Google Scholar
  133. D. Basu, K. T. Montone, L. P. Wang et al., “Detecting and targeting mesenchymal-like subpopulations within squamous cell carcinomas,” Cell Cycle, vol. 10, no. 12, pp. 2008–2016, 2011. View at Publisher · View at Google Scholar · View at Scopus
  134. K. Ketola, M. Hilvo, T. Hyotylainen, et al., “Salinomycin inhibits prostate cancer growth and migration via induction of oxidative stress,” British Journal of Cancer, vol. 106, no. 1, pp. 99–106, 2012. View at Publisher · View at Google Scholar
  135. S. A. Waksman, The Actinomycetes. Classification, Identification and Descriptions of Genera and Species, vol. 2, The Williams and Wilkins, Baltimore, mD, USA, 1961.
  136. H. D. Danforth, M. D. Ruff, W. M. Reid, and R. L. Miller, “Anticoccidial activity of salinomycin in battery raised broiler chickens,” Poultry science, vol. 56, no. 3, pp. 926–932, 1977. View at Scopus
  137. H. Mehlhorn, H. J. Ganster, and W. Raether, “Effect of salinomycin-Na on malaria parasites (Plasmodium falciparum and P. berghei),” Zentralblatt fur Bakteriologie Mikrobiologie und Hygiene A, vol. 256, no. 3, pp. 305–313, 1984. View at Scopus
  138. Y. Miyazaki, J. Nagatsu, H. Sugawara, and M. Shibuya, Japanese Patent Publication, no. 25392, 1972.
  139. A. Daugschies, U. Gässlein, and M. Rommel, “Comparative efficacy of anticoccidials under the conditions of commercial broiler production and in battery trials,” Veterinary Parasitology, vol. 76, no. 3, pp. 163–171, 1998. View at Publisher · View at Google Scholar · View at Scopus
  140. P. Butaye, L. A. Devriese, and F. Haesebrouck, “Antimicrobial growth promoters used in animal feed: effects of less well known antibiotics on gram-positive bacteria,” Clinical Microbiology Reviews, vol. 16, no. 2, pp. 175–188, 2003. View at Publisher · View at Google Scholar · View at Scopus
  141. T. R. Callaway, T. S. Edrington, J. L. Rychlik et al., “Ionophores: their use as ruminant growth promotants and impact on food safety,” Current Issues in Intestinal Microbiology, vol. 4, no. 2, pp. 43–51, 2003. View at Scopus
  142. M. Jenkins, S. Klopp, D. Ritter, K. Miska, and R. Fetterer, “Comparison of Eimeria species distribution and salinomycin resistance in commercial broiler operations utilizing different coccidiosis control strategies,” Avian Diseases, vol. 54, no. 3, pp. 1002–1006, 2010. View at Publisher · View at Google Scholar · View at Scopus
  143. M. Mitani, T. Yamanishi, and Y. Miyazaki, “Salinomycin: a new monovalent cation ionophore,” Biochemical and Biophysical Research Communications, vol. 66, no. 4, pp. 1231–1236, 1975. View at Scopus
  144. M. Mitani, T. Yamanishi, Y. Miyazaki, and N. Otake, “Salinomycin effects on mitochondrial ion translocation and respiration,” Antimicrobial Agents and Chemotherapy, vol. 9, no. 4, pp. 655–660, 1976. View at Scopus
  145. B. C. Pressman and F. A. Lattanzio, “Cardiovascular effects of ionophores,” in Frontiers of Biological Energetics, P. L. Dutton, J. S. Leigh, and A. Scarpa, Eds., vol. 2, pp. 1245–1252, Academic Press, New York, NY, USA, 1978.
  146. M. S. Gaide, J. T. Lehr, and S. S. Wong, “Comparative study of the effects of salinomycin and monensin on electrophysiologic and contractile properties of canine myocardium,” European Journal of Pharmacology, vol. 100, no. 3-4, pp. 321–327, 1984. View at Scopus
  147. M. Fahim, G. Del Valle, and B. C. Pressman, “Comparison of the effects of the ionophore salinomycin and adrenaline on the haemodynamics and work efficiency of the dog heart,” Cardiovascular Research, vol. 20, no. 2, pp. 145–152, 1986. View at Scopus
  148. P. J. Kocieński, R. C. D. Brown, A. Pommier, M. Procter, and B. Schmidt, “Synthesis of salinomycin,” Journal of the Chemical Society, no. 1, pp. 9–39, 1998. View at Scopus
  149. A. Huczynski, J. Janczak, J. Stefanska, M. Antoszczak, and B. Brzezinski, “Synthesis and antimicrobial activity of amide derivatives of polyether antibiotic-salinomycin,” Bioorganic and Medical Chemistry Letters, vol. 22, no. 14, pp. 4697–4702, 2012. View at Publisher · View at Google Scholar
  150. J. Rollinson, F. G. R. Taylor, and J. Chesney, “Salinomycin poisoning in horses,” Veterinary Record, vol. 121, no. 6, pp. 126–128, 1987. View at Scopus
  151. K. H. Plumlee, B. Johnson, and F. D. Galey, “Acute salinomycin toxicosis of pigs,” Journal of Veterinary Diagnostic Investigation, vol. 7, no. 3, pp. 419–420, 1995. View at Scopus
  152. J. S. Van der Linde-Sipman, T. S. G. A. M. Van den Inch, J. J. Van Nes et al., “Salinomycin-induced polyneuropathy in cats: morphologic and epidemiologic data,” Veterinary Pathology, vol. 36, no. 2, pp. 152–156, 1999. View at Scopus
  153. M. E. Kosal and D. E. Anderson, “An unaddressed issue of agricultural terrorism: a case study on feed security,” Journal of Animal Science, vol. 82, no. 11, pp. 3394–3400, 2004. View at Scopus
  154. M. Aleman, K. G. Magdesian, T. S. Peterson, and F. D. Galey, “Salinomycin toxicosis in horses,” Journal of the American Veterinary Medical Association, vol. 230, no. 12, pp. 1822–1826, 2007. View at Publisher · View at Google Scholar · View at Scopus
  155. P. A. Story and A. Doube, “A case of human poisoning by salinomycin, an agricultural antibiotic,” New Zealand Medical Journal, vol. 117, no. 1190, 2004. View at Scopus
  156. J. L. C. M. Dorne, M. L. Fernández-Cruz, U. Bertelsen et al., “Risk assessment of coccidostatics during feed cross-contamination: animal and human health aspects,” Toxicology and Applied Pharmacology, 2011. View at Publisher · View at Google Scholar · View at Scopus
  157. B. Elenbaas, L. Spirio, F. Koerner et al., “Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells,” Genes and Development, vol. 15, no. 1, pp. 50–65, 2001. View at Publisher · View at Google Scholar · View at Scopus
  158. S. A. Mani, W. Guo, M. J. Liao et al., “The epithelial-mesenchymal transition generates cells with properties of stem cells,” Cell, vol. 133, no. 4, pp. 704–715, 2008. View at Publisher · View at Google Scholar · View at Scopus
  159. T. T. Onder, P. B. Gupta, S. A. Mani, J. Yang, E. S. Lander, and R. A. Weinberg, “Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways,” Cancer Research, vol. 68, no. 10, pp. 3645–3654, 2008. View at Publisher · View at Google Scholar · View at Scopus
  160. K. Polyak and R. A. Weinberg, “Transitions between epithelial and mesenchymal states: Acquisition of malignant and stem cell traits,” Nature Reviews Cancer, vol. 9, no. 4, pp. 265–273, 2009. View at Publisher · View at Google Scholar · View at Scopus
  161. R. Liu, X. Wang, G. Y. Chen et al., “The prognostic role of a gene signature from tumorigenic breast-cancer cells,” New England Journal of Medicine, vol. 356, no. 3, pp. 217–226, 2007. View at Publisher · View at Google Scholar · View at Scopus
  162. M. Shipitsin, L. L. Campbell, P. Argani et al., “Molecular definition of breast tumor heterogeneity,” Cancer Cell, vol. 11, no. 3, pp. 259–273, 2007. View at Publisher · View at Google Scholar · View at Scopus
  163. G. Dontu, W. M. Abdallah, J. M. Foley et al., “In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells,” Genes and Development, vol. 17, no. 10, pp. 1253–1270, 2003. View at Publisher · View at Google Scholar · View at Scopus
  164. M. Dean, T. Fojo, and S. Bates, “Tumour stem cells and drug resistance,” Nature Reviews Cancer, vol. 5, no. 4, pp. 275–284, 2005. View at Publisher · View at Google Scholar · View at Scopus
  165. A. Elliot, J. Adams, and M. Al-Hajj, “The ABCs of cancer stem cell drug resistance,” IDrugs, vol. 13, no. 9, pp. 632–635, 2010. View at Scopus
  166. A. Gronchi, J. Y. Blay, and J. C. Trent, “The role of high-dose imatinib in the management of patients with gastrointestinal stromal tumor,” Cancer, vol. 116, no. 8, pp. 1847–1858, 2010. View at Publisher · View at Google Scholar · View at Scopus
  167. W. K. Kim, J. H. Kim, K. Yoon et al., “Salinomycin, a p-glycoprotein inhibitor, sensitizes radiation-treated cancer cells by increasing DNA damage and inducing G2 arrest,” Investigational New Drugs, pp. 1–8, 2011. View at Publisher · View at Google Scholar · View at Scopus
  168. R. Riccioni, M. L. Dupuis, M. Bernabei et al., “The cancer stem cell selective inhibitor salinomycin is a p-glycoprotein inhibitor,” Blood Cells, Molecules, and Diseases, vol. 45, no. 1, pp. 86–92, 2010. View at Publisher · View at Google Scholar · View at Scopus
  169. L. Vermeulen, F. De Sousa E Melo, M. Van Der Heijden et al., “Wnt activity defines colon cancer stem cells and is regulated by the microenvironment,” Nature Cell Biology, vol. 12, no. 5, pp. 468–476, 2010. View at Publisher · View at Google Scholar · View at Scopus
  170. P. Wend, J. D. Holland, U. Ziebold, and W. Birchmeier, “Wnt signaling in stem and cancer stem cells,” Seminars in Cell and Developmental Biology, vol. 21, no. 8, pp. 855–863, 2010. View at Publisher · View at Google Scholar · View at Scopus
  171. M. S. Chen, W. A. Woodward, F. Behbod et al., “Wnt/β-catenin mediates radiation resistance of Sca1+ progenitors in an immortalized mammary gland cell line,” Journal of Cell Science, vol. 120, no. 3, pp. 468–477, 2007. View at Publisher · View at Google Scholar · View at Scopus
  172. W. A. Woodward, M. S. Chen, F. Behbod, M. P. Alfaro, T. A. Buchholz, and J. M. Rosen, “WNT/β-catenin mediates radiation resistance of mouse mammary progenitor cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 2, pp. 618–623, 2007. View at Publisher · View at Google Scholar · View at Scopus
  173. O. Warburg, K. Posener, and E. Negelein, “Uber den stoffwechsel von tumoren,” Biochemische Zeitschrift, vol. 152, pp. 319–344, 1924.
  174. J. M. Funes, M. Quintero, S. Henderson et al., “Transformation of human mesenchymal stem cells increases their dependency on oxidative phosphorylation for energy production,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 15, pp. 6223–6228, 2007. View at Publisher · View at Google Scholar · View at Scopus
  175. E. Vlashi, C. Lagadec, L. Vergnes, et al., “Metabolic state of glioma stem cells and nontumorigenic cells,” Proceedings of the National Academy of Science USA, vol. 108, no. 38, pp. 16062–16067, 2011. View at Publisher · View at Google Scholar
  176. H. Li, L. Liu, L. Guo et al., “HERG K+ channel expression in CD34+/CD38 -/CD123high cells and primary leukemia cells and analysis of its regulation in leukemia cells,” International Journal of Hematology, vol. 87, no. 4, pp. 387–392, 2008. View at Publisher · View at Google Scholar · View at Scopus
  177. J. H. Park, S. J. Park, M. K. Chung et al., “High expression of large-conductance Ca2+-activated K+ channel in the CD133+ subpopulation of SH-SY5Y neuroblastoma cells,” Biochemical and Biophysical Research Communications, vol. 396, no. 3, pp. 637–642, 2010. View at Publisher · View at Google Scholar · View at Scopus
  178. C. D. Bortner, F. M. Hughes, and J. A. Cidlowski, “A primary role for K+ and Na+ efflux in the activation of apoptosis,” Journal of Biological Chemistry, vol. 272, no. 51, pp. 32436–32442, 1997. View at Publisher · View at Google Scholar · View at Scopus
  179. B. Andersson, V. Janson, P. Behnam-Motlagh, R. Henriksson, and K. Grankvist, “Induction of apoptosis by intracellular potassium ion depletion: using the fluorescent dye PBFI in a 96-well plate method in cultured lung cancer cells,” Toxicology in Vitro, vol. 20, no. 6, pp. 986–994, 2006. View at Publisher · View at Google Scholar · View at Scopus
  180. A. P. Feinberg, R. Ohlsson, and S. Henikoff, “The epigenetic progenitor origin of human cancer,” Nature Reviews Genetics, vol. 7, no. 1, pp. 21–33, 2006. View at Publisher · View at Google Scholar · View at Scopus
  181. P. Vineis, A. Schatzkin, and J. D. Potter, “Models of carcinogenesis: an overview,” Carcinogenesis, vol. 31, no. 10, pp. 1703–1709, 2010. View at Publisher · View at Google Scholar · View at Scopus
  182. D. Hanahan and R. A. Weinberg, “Hallmarks of cancer: the next generation,” Cell, vol. 144, no. 5, pp. 646–674, 2011. View at Publisher · View at Google Scholar · View at Scopus
  183. R. Kanwal and S. Gupta, “Epigenetic modifications in cancer,” Clinical Genetetics, vol. 81, no. 4, pp. 303–311, 2012.
  184. J. E. Visvader, “Cells of origin in cancer,” Nature, vol. 469, no. 7330, pp. 314–322, 2011. View at Publisher · View at Google Scholar · View at Scopus
  185. A. Vincent and I. Van Seuningen, “On the epigenetic origin of cancer stem cells,” Biochimica et Biophysica Acta, vol. 1826, no. 1, pp. 83–88, 2012.
  186. T. Tanei, K. Morimoto, K. Shimazu et al., “Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential paclitaxel and epirubicin-based chemotherapy for breast cancers,” Clinical Cancer Research, vol. 15, no. 12, pp. 4234–4241, 2009. View at Publisher · View at Google Scholar · View at Scopus
  187. R. Bhatia, M. Holtz, N. Niu et al., “Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment,” Blood, vol. 101, no. 12, pp. 4701–4707, 2003. View at Scopus
  188. P. L. Bedard, F. Cardoso, and M. J. Piccart-Gebhart, “Stemming resistance to HER-2 targeted therapy,” Journal of Mammary Gland Biology and Neoplasia, vol. 14, no. 1, pp. 55–66, 2009. View at Publisher · View at Google Scholar · View at Scopus
  189. A. Parmar, S. Marz, S. Rushton et al., “Stromal niche cells protect early leukemic FLT3-ITD+ progenitor cells against first-generation FLT3 tyrosine kinase inhibitors,” Cancer Research, vol. 71, no. 13, pp. 4696–4706, 2011. View at Publisher · View at Google Scholar · View at Scopus